Skip to main content

Table 1 Distribution of the clinical characteristics of the patient sample group (DC cohort; n = 11) for age, EDSS, PerfOs, and PROs prior to MIS416 treatment

From: Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study

 

Median

Minimum

Maximum

Age (years) (n = 11)

53

46

60

EDSS

6

4

7

aGait speed (m/s)

0.68

0.26

1.19

NHPT (s)

28.5

19.8

152.3

bPASAT (errors)

37

23

60

cSF-36 [Norm]/100

 General health [75]

46.1

23.7

65.1

 Physical function [82]

23.1

19.3

40.3

 Bodily pain [75]

42.6

30.6

62

 Role physical [81]

30.2

2.5

39.2

 Role emotional [88]

45.7

17.9

56.2

 Social function [88]

37.3

17.2

57.3

 Vitality [68]

40.7

25.9

52.6

 Mental health [80]

50.9

29.9

61.3

  1. a n = 10
  2. bMaximum score possible = 60
  3. cHigher = better health